SCHEMBL3985145

SCHEMBL3985145

O=C(O)CNc1ccccc1C(=O)C(=O)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.45
TDP1 Q9NUW8 3/20 0.44
HTT P42858 3/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
KDM4E B2RXH2 2/20 0.43
AGTR1 P30556 1/20 0.43
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
MAPK1 P28482 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1784054 0.85 ALDH1A1 (0.59) ALDH1A1TDP1HTTRAB9ANPC1
SCHEMBL11790901 0.84 ALDH1A1 (0.58) ALDH1A1TDP1HTTRAB9ANPC1
Dimethylamine SCHEMBL1788162 0.82 ALDH1A1 (0.55) ALDH1A1TDP1HTTRAB9ANPC1
SCHEMBL5707628 0.78 POLB (0.56) ALDH1A1HTTRAB9ANPC1KDM4E
SCHEMBL19860933 0.77 KMT2A (0.59) ALDH1A1TDP1HTTRAB9ANPC1
SCHEMBL21367571 0.75 TDP1 (0.70) ALDH1A1TDP1KDM4EMAPK1L3MBTL1
SCHEMBL9686341 0.75 KMT2A (0.58) ALDH1A1TDP1HTTNPC1KDM4E
SCHEMBL29620333 0.74 KDM4E (0.71) ALDH1A1RAB9AKDM4EAGTR1L3MBTL1
SCHEMBL341645 0.74 KDM4E (0.71) ALDH1A1RAB9AKDM4EAGTR1L3MBTL1
SCHEMBL10333082 0.74 ALDH1A1 (0.56) ALDH1A1TDP1HTTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515972-B1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY HOFFMANN LA ROCHE (CH) 2009-05-13 EP disclosed
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1515972-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed
WO-2003106459-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL ALDH1A1 297/4885TDP1 2265/4885HTT 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.